Northern Financial Advisors Inc Sells 791 Shares of Eli Lilly and Company $LLY

Northern Financial Advisors Inc cut its holdings in Eli Lilly and Company (NYSE:LLY) by 39.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 1,217 shares of the company’s stock after selling 791 shares during the period. Eli Lilly and Company comprises about 1.5% of Northern Financial Advisors Inc’s holdings, making the stock its 17th largest holding. Northern Financial Advisors Inc’s holdings in Eli Lilly and Company were worth $1,308,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Family Capital Management Inc. boosted its stake in Eli Lilly and Company by 17.0% in the fourth quarter. Family Capital Management Inc. now owns 714 shares of the company’s stock valued at $767,000 after acquiring an additional 104 shares during the last quarter. Wealthspan Partners LLC boosted its stake in Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock valued at $2,268,000 after acquiring an additional 10 shares during the last quarter. Stevens Capital Partners bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $213,000. Ticino Wealth bought a new position in Eli Lilly and Company in the fourth quarter valued at approximately $1,312,000. Finally, Breachway Investments LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth $652,000. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Down 3.6%

Shares of NYSE LLY opened at $884.88 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The company’s fifty day moving average is $958.83 and its 200-day moving average is $983.91. The stock has a market cap of $836.05 billion, a price-to-earnings ratio of 38.56, a P/E/G ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the business posted $5.32 earnings per share. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 33.9 EPS for the current year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly’s obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LLY. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Tuesday, March 10th. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 price target on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Friday, March 13th. The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $1,313.00 to $1,327.00 and gave the stock an “overweight” rating in a research report on Friday, April 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,225.33.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.